Page last updated: 2024-12-06
2-cresolphthalexon
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2-cresolphthalexon: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 75485 |
SCHEMBL ID | 8654467 |
MeSH ID | M0068918 |
Synonyms (37)
Synonym |
---|
2411-89-4 |
cresolphthalexon |
nsc298195 |
glycine,n'-[(3-oxo-1(3h)-isobenzofuranylidene)bis[(6-hydroxy-5-methyl-3,1-phenylene)methylene]]bis[n-(carboxymethyl)- |
3,n-di(carboxymethyl)aminomethyl]-o-cresolphthalein |
phenolphthalein,3''-bis[[bis(carboxymethyl)amino]methyl]-5',5''-dimethyl- |
o-cresolphthalexon |
nsc-298195 |
2-cresolphthalexon |
2-[[5-[1-[3-[[bis(carboxymethyl)amino]methyl]-4-hydroxy-5-methylphenyl]-3-oxo-2-benzofuran-1-yl]-2-hydroxy-3-methylphenyl]methyl-(carboxymethyl)amino]acetic acid |
2-[[5-[1-[3-[[bis(carboxymethyl)amino]methyl]-4-hydroxy-5-methyl-phenyl]-3-oxo-isobenzofuran-1-yl]-2-hydroxy-3-methyl-phenyl]methyl-(carboxymethyl)amino]acetic acid |
A817106 |
1,3-dihydro-3-oxoisobenzofuran-1-ylidenebis(6-hydroxy-5-methyl-m-phenylenemethylenenitrilo)tetra-acetic acid |
a4p6737i7f , |
unii-a4p6737i7f |
nsc 298195 |
n,n'-((3-oxo-1(3h)-isobenzofuranylidene)bis((6-hydroxy-5-methyl-3,1-phenylene)methylene))bis(n-(carboxymethyl)glycine |
einecs 219-318-8 |
3,3'-bis(n,n-di(carboxymethyl)aminomethyl)-o-cresolphthalein |
glycine, n,n'-((3-oxo-1(3h)-isobenzofuranylidene)bis((6-hydroxy-5-methyl-3,1-phenylene)methylene))bis(n-(carboxymethyl)- |
FT-0634254 |
AKOS015903248 |
3,3'-bis(n,n-bis(carboxymethyl)aminomethyl)-o-cresolphthalein |
n,n'-((3-oxo-1(3h)-isobenzofuranylidene)bis((6-hydroxy-5-methyl-3,1-phenylene)methylene))bis(n-(carboxymethyl)glycine) |
o-cresolphthalexone |
glycine, n,n'-[(3-oxo-1(3h)-isobenzofuranylidene)bis[(6-hydroxy-5-methyl-3,1-phenylene)methylene]]bis[n-(carboxymethyl)- |
DTXSID5062392 |
SCHEMBL8654467 |
J-610053 |
mfcd00005911 |
glycine,n,n'-[(3-oxo-1(3h)-isobenzofuranylidene)bis[(6-hydroxy-5-methyl-3,1-phenylene)methylene]]bis[n-(carboxymethyl)- |
Q907634 |
2,2',2'',2'''-(5,5'-(3-oxo-1,3-dihydroisobenzofuran-1,1-diyl)bis(2-hydroxy-3-methyl-5,1-phenylene))bis(methylene)bis(azanetriyl)tetraacetic acid |
BS-43771 |
CS-0169030 |
phthalate complexing agent [chelation indicator] |
HY-W110896 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Serum calcium was dosed in duplicate by conventional colorimetric techniques involving o-cresol-phthalein complexone (OCP) or methylthymol blue (MTB) as reagents." | ( Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. Berthommier, C; Corot, C; Devoldere, L; Diai, A; Idee, JM; Lin, J; Port, M; Raynal, I; Robert, M, 1999) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (21)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 9 (42.86) | 18.7374 |
1990's | 4 (19.05) | 18.2507 |
2000's | 4 (19.05) | 29.6817 |
2010's | 3 (14.29) | 24.3611 |
2020's | 1 (4.76) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.33
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.33) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.55%) | 6.00% |
Case Studies | 1 (4.55%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (90.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |